all 0 3 0 3 O
adult 4 9 4 9 O
patients 10 18 10 18 O
with 19 23 19 23 O
a 24 25 24 25 O
nasal 26 31 26 31 B-chronic_disease
or 32 34 32 34 I-chronic_disease
facial 35 41 35 41 I-chronic_disease
skin 42 46 42 46 I-chronic_disease
/ 46 47 46 47 I-chronic_disease
soft 47 51 47 51 I-chronic_disease
tissue 52 58 52 58 I-chronic_disease
defect 59 65 59 65 I-chronic_disease
requiring 66 75 66 75 O
reconstruction 76 90 76 90 B-treatment
limited 91 98 91 98 O
to 99 101 99 101 O
or 102 104 102 104 O
including 105 114 105 114 O
a 115 116 115 116 O
full 117 121 117 121 B-treatment
- 121 122 121 122 I-treatment
thickness 122 131 122 131 I-treatment
skin 132 136 132 136 I-treatment
graft 137 142 137 142 I-treatment

current 0 7 143 150 O
or 8 10 151 153 O
recent 11 17 154 160 O
( 18 19 161 162 O
within 19 25 162 168 O
one 26 29 169 172 B-upper_bound
week 30 34 173 177 I-upper_bound
of 35 37 178 180 O
surgery 38 45 181 188 B-treatment
) 45 46 188 189 O
systemic 47 55 190 198 B-treatment
antibiotic 56 66 199 209 I-treatment
use 67 70 210 213 O
, 70 71 213 214 O
intolerance 72 83 215 226 O
to 84 86 227 229 O
both 87 91 230 234 O
clindamycin 92 103 235 246 B-treatment
and 104 107 247 250 O
cephalexin 108 118 251 261 B-treatment
, 118 119 261 262 O
discovery 120 129 263 272 O
of 130 132 273 275 O
a 133 134 276 277 O
persistent 135 145 278 288 O
cutaneous 146 155 289 298 B-cancer
malignancy 156 166 299 309 I-cancer
at 167 169 310 312 O
the 170 173 313 316 O
site 174 178 317 321 O
of 179 181 322 324 O
the 182 185 325 328 O
defect 186 192 329 335 O
following 193 202 336 345 O
the 203 206 346 349 O
reconstructive 207 221 350 364 B-treatment
procedure 222 231 365 374 I-treatment
and 232 235 375 378 O
previous 236 244 379 387 O
reconstruction 245 259 388 402 O
at 260 262 403 405 O
the 263 266 406 409 O
site 267 271 410 414 O
of 272 274 415 417 O
the 275 278 418 421 O
skin 279 283 422 426 O
/ 283 284 426 427 O
soft 284 288 427 431 O
- 288 289 431 432 O
tissue 289 295 432 438 O
defect 296 302 439 445 O

